Role of cytoreductive surgery in recurrent ovarian cancer

Anna Fagotti, Valerio Gallotta, Federico Romano, Francesco Fanfani, Cristiano Rossitto, Giuseppe Vizzielli, Barbara Costantini, Giovanni Scambia

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Ovarian cancer is the leading cause of death from gynecologic malignancy in western countries, primarily because over 60% of patients with ovarian cancer will experience disease recurrence. Primary cytoreductive surgery and combination chemotherapy are the cornerstones of the initial treatment for epithelial ovarian cancer. The management of recurrent ovarian cancer is less clear than that of primary disease. The management of recurrent ovarian cancer is largely based on systemic chemotherapy, with surgery being offered only in selected individuals. Despite this, the benefits of surgery has been shown in a meta-analysis by Bristow et al. where the survival is influenced by the completeness of cytoreduction. Therefore, epithelial ovarian cancer can be accepted as a chronic disease that consists of multiple recurrence and retreatments such as further surgeries and chemotherapies. The clinical applicability of this secondary surgery remains a controversial topic. Therefore, a trial on secondary surgery for recurrent ovarian cancer and the role of hyperthermic intraoperative peritoneal chemotherapy in addition to the current standard of care of administering systemic chemotherapy alone is warranted. The current data supported that the selection criteria to offer secondary cytoreduction represents one of the most important challenges. There are, to date, no Phase III trials that demonstrate the clinical utility of either secondary surgical cytoreduction or hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer.

Original languageEnglish
Pages (from-to)87-95
Number of pages9
JournalTherapy
Volume7
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Ovarian Neoplasms
Drug Therapy
Recurrence
Phase III Clinical Trials
Retreatment
Standard of Care
Combination Drug Therapy
Patient Selection
Meta-Analysis
Cause of Death
Survival
Ovarian epithelial cancer
Neoplasms

Keywords

  • Gynecologic oncology
  • HIPEC
  • Hyperthermic intraoperative peritoneal chemotherapy
  • Recurrent ovarian cancer
  • Secondary cytoreduction

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Fagotti, A., Gallotta, V., Romano, F., Fanfani, F., Rossitto, C., Vizzielli, G., ... Scambia, G. (2010). Role of cytoreductive surgery in recurrent ovarian cancer. Therapy, 7(1), 87-95. https://doi.org/10.2217/thy.09.90

Role of cytoreductive surgery in recurrent ovarian cancer. / Fagotti, Anna; Gallotta, Valerio; Romano, Federico; Fanfani, Francesco; Rossitto, Cristiano; Vizzielli, Giuseppe; Costantini, Barbara; Scambia, Giovanni.

In: Therapy, Vol. 7, No. 1, 01.2010, p. 87-95.

Research output: Contribution to journalArticle

Fagotti, A, Gallotta, V, Romano, F, Fanfani, F, Rossitto, C, Vizzielli, G, Costantini, B & Scambia, G 2010, 'Role of cytoreductive surgery in recurrent ovarian cancer', Therapy, vol. 7, no. 1, pp. 87-95. https://doi.org/10.2217/thy.09.90
Fagotti A, Gallotta V, Romano F, Fanfani F, Rossitto C, Vizzielli G et al. Role of cytoreductive surgery in recurrent ovarian cancer. Therapy. 2010 Jan;7(1):87-95. https://doi.org/10.2217/thy.09.90
Fagotti, Anna ; Gallotta, Valerio ; Romano, Federico ; Fanfani, Francesco ; Rossitto, Cristiano ; Vizzielli, Giuseppe ; Costantini, Barbara ; Scambia, Giovanni. / Role of cytoreductive surgery in recurrent ovarian cancer. In: Therapy. 2010 ; Vol. 7, No. 1. pp. 87-95.
@article{9561188b8a5b4eac980e47f5ed7b5ddf,
title = "Role of cytoreductive surgery in recurrent ovarian cancer",
abstract = "Ovarian cancer is the leading cause of death from gynecologic malignancy in western countries, primarily because over 60{\%} of patients with ovarian cancer will experience disease recurrence. Primary cytoreductive surgery and combination chemotherapy are the cornerstones of the initial treatment for epithelial ovarian cancer. The management of recurrent ovarian cancer is less clear than that of primary disease. The management of recurrent ovarian cancer is largely based on systemic chemotherapy, with surgery being offered only in selected individuals. Despite this, the benefits of surgery has been shown in a meta-analysis by Bristow et al. where the survival is influenced by the completeness of cytoreduction. Therefore, epithelial ovarian cancer can be accepted as a chronic disease that consists of multiple recurrence and retreatments such as further surgeries and chemotherapies. The clinical applicability of this secondary surgery remains a controversial topic. Therefore, a trial on secondary surgery for recurrent ovarian cancer and the role of hyperthermic intraoperative peritoneal chemotherapy in addition to the current standard of care of administering systemic chemotherapy alone is warranted. The current data supported that the selection criteria to offer secondary cytoreduction represents one of the most important challenges. There are, to date, no Phase III trials that demonstrate the clinical utility of either secondary surgical cytoreduction or hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer.",
keywords = "Gynecologic oncology, HIPEC, Hyperthermic intraoperative peritoneal chemotherapy, Recurrent ovarian cancer, Secondary cytoreduction",
author = "Anna Fagotti and Valerio Gallotta and Federico Romano and Francesco Fanfani and Cristiano Rossitto and Giuseppe Vizzielli and Barbara Costantini and Giovanni Scambia",
year = "2010",
month = "1",
doi = "10.2217/thy.09.90",
language = "English",
volume = "7",
pages = "87--95",
journal = "Therapy",
issn = "1475-0708",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Role of cytoreductive surgery in recurrent ovarian cancer

AU - Fagotti, Anna

AU - Gallotta, Valerio

AU - Romano, Federico

AU - Fanfani, Francesco

AU - Rossitto, Cristiano

AU - Vizzielli, Giuseppe

AU - Costantini, Barbara

AU - Scambia, Giovanni

PY - 2010/1

Y1 - 2010/1

N2 - Ovarian cancer is the leading cause of death from gynecologic malignancy in western countries, primarily because over 60% of patients with ovarian cancer will experience disease recurrence. Primary cytoreductive surgery and combination chemotherapy are the cornerstones of the initial treatment for epithelial ovarian cancer. The management of recurrent ovarian cancer is less clear than that of primary disease. The management of recurrent ovarian cancer is largely based on systemic chemotherapy, with surgery being offered only in selected individuals. Despite this, the benefits of surgery has been shown in a meta-analysis by Bristow et al. where the survival is influenced by the completeness of cytoreduction. Therefore, epithelial ovarian cancer can be accepted as a chronic disease that consists of multiple recurrence and retreatments such as further surgeries and chemotherapies. The clinical applicability of this secondary surgery remains a controversial topic. Therefore, a trial on secondary surgery for recurrent ovarian cancer and the role of hyperthermic intraoperative peritoneal chemotherapy in addition to the current standard of care of administering systemic chemotherapy alone is warranted. The current data supported that the selection criteria to offer secondary cytoreduction represents one of the most important challenges. There are, to date, no Phase III trials that demonstrate the clinical utility of either secondary surgical cytoreduction or hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer.

AB - Ovarian cancer is the leading cause of death from gynecologic malignancy in western countries, primarily because over 60% of patients with ovarian cancer will experience disease recurrence. Primary cytoreductive surgery and combination chemotherapy are the cornerstones of the initial treatment for epithelial ovarian cancer. The management of recurrent ovarian cancer is less clear than that of primary disease. The management of recurrent ovarian cancer is largely based on systemic chemotherapy, with surgery being offered only in selected individuals. Despite this, the benefits of surgery has been shown in a meta-analysis by Bristow et al. where the survival is influenced by the completeness of cytoreduction. Therefore, epithelial ovarian cancer can be accepted as a chronic disease that consists of multiple recurrence and retreatments such as further surgeries and chemotherapies. The clinical applicability of this secondary surgery remains a controversial topic. Therefore, a trial on secondary surgery for recurrent ovarian cancer and the role of hyperthermic intraoperative peritoneal chemotherapy in addition to the current standard of care of administering systemic chemotherapy alone is warranted. The current data supported that the selection criteria to offer secondary cytoreduction represents one of the most important challenges. There are, to date, no Phase III trials that demonstrate the clinical utility of either secondary surgical cytoreduction or hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer.

KW - Gynecologic oncology

KW - HIPEC

KW - Hyperthermic intraoperative peritoneal chemotherapy

KW - Recurrent ovarian cancer

KW - Secondary cytoreduction

UR - http://www.scopus.com/inward/record.url?scp=75449114678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75449114678&partnerID=8YFLogxK

U2 - 10.2217/thy.09.90

DO - 10.2217/thy.09.90

M3 - Article

AN - SCOPUS:75449114678

VL - 7

SP - 87

EP - 95

JO - Therapy

JF - Therapy

SN - 1475-0708

IS - 1

ER -